Skip to content

US · RLAY · BIOTECHNOLOGY

Relay Therapeutics, Inc. (RLAY) intrinsic value and stock valuation

$16.12as of 2026-11-21 · Mkt cap 3.45B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Relay Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values RLAY with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from RLAY’s statements →

Relay Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 relaytx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$15.4M-28.6% 5y CAGRd
20182025
Net income
-$-276.48M
20182025
Free cash flow
-$-235.87M
20182025
Total equity
$567.1M-5.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$15.4M$10M$25.6M$1.38M$3.03M
Operating income-$-302.74M-$-372.47M-$-373M-$-299.27M-$-364.7M
Net income-$-276.48M-$-337.71M-$-341.97M-$-290.51M-$-363.87M
EPSd-$-1.61M-$-2.36M-$-2.79M-$-2.59M-$-3.82M
Operating cash flow-$-235.46M-$-249.11M-$-300.32M-$-229.49M-$-74.41M
Capital expenditure-$-410K-$-2.02M-$-4.13M-$-9.06M-$-3.47M
Free cash flow-$-235.87M-$-251.12M-$-304.44M-$-238.55M-$-77.88M
Total assets$621.3M$871.3M$844M$1.1B$1.01B
Total debt$32.5M$48.5M$53.5M$57.7M$22.9M
Net debt-$-51.56M-$-75.78M-$-90.27M-$-94.05M-$-257.22M
Total equity$567.1M$777.8M$752M$950.2M$897.8M
Cash and short-term investments$554.5M$781.3M$750.1M$998.9M$958.1M
Income statement
20252024202320222021
Revenue$15.4M$10M$25.6M$1.38M$3.03M
Cost of revenue$3.56M$315.4M$326.4M$243M$169.4M
Gross profit$11.8M-$-305.43M-$-300.84M-$-241.62M-$-166.36M
Research and development expenses$261.4M$319.1M$330M$246.4M$295.7M
Selling, general and administrative expenses$56.7M$80.2M$78.6M$69.3M$59.8M
Other expenses-$-3.56M-$-332.3M-$-336.44M-$-258.03M-$-157.06M
Operating expenses$314.5M$67M$72.2M$57.7M$198.3M
Cost and expenses$318.1M$382.5M$398.6M$300.7M$367.7M
Interest income$27M$34.8M$31.1M$8.79M$830K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.56M$5.46M$5.27M$4.13M$3.92M
Ebitda-$-272.92M-$-380.21M-$-374.15M-$-306.82M-$-223.08M
Operating income-$-302.74M-$-372.47M-$-373M-$-299.27M-$-364.7M
Total other income/expenses, net$26.3M$34.8M$31M$8.77M$830K
Income before tax-$-276.48M-$-337.71M-$-341.97M-$-290.51M-$-363.87M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-276.48M-$-337.71M-$-341.97M-$-290.51M-$-363.87M
Weighted average shares outstanding$171.6M$142.9M$122.6M$112.2M$95.1M
Weighted average diluted shares outstanding$171.6M$142.9M$122.6M$112.2M$95.1M
Balance sheet
20252024202320222021
Cash and short-term investments$554.5M$781.3M$750.1M$998.9M$958.1M
Net receivables$0.00$0.00$0.00$5.22M$4.94M
Inventory$0.00$0.00$0.00$12.1M$0.00
Total current assets$578.3M$809.2M$770.1M$1.02B$976.2M
Property, plant and equipment, net$41.7M$57.7M$68.9M$75.4M$27.3M
Goodwill and intangible assets$0.00$2.3M$2.3M$2.3M$2.3M
Long-term investments$1.34M$0.00$2.71M$2.58M$0.00
Total non-current assets$43.1M$62.1M$73.9M$80.3M$32.2M
Total assets$621.3M$871.3M$844M$1.1B$1.01B
Accounts payable$7.71M$14.1M$9.21M$10.6M$8.28M
Short-term debt$3.77M$5.73M$4.96M$4.28M$1.84M
Deferred revenue$0.00$7.68M$0.00$0.00$250K
Total current liabilities$25.6M$50.7M$30.3M$63.7M$24.3M
Long-term debt$28.7M$42.8M$48.5M$53.5M$21.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$28.7M$42.8M$61.7M$85.8M$86.3M
Capital lease obligations$32.5M$48.5M$53.5M$57.7M$22.9M
Total liabilities$54.3M$93.5M$92M$149.6M$110.6M
Common stock$170K$170K$130K$120K$110K
Retained earnings-$-2.01B-$-1.74B-$-1.4B-$-1.06B-$-768.1M
Accumulated other comprehensive income (loss)$730K-$-990K-$-200K-$-10.42M-$-1.09M
Total equity$567.1M$777.8M$752M$950.2M$897.8M
Total investments$471.8M$657M$606.4M$849.7M$678M
Total debt$32.5M$48.5M$53.5M$57.7M$22.9M
Net debt-$-51.56M-$-75.78M-$-90.27M-$-94.05M-$-257.22M
Cash flow statement
20252024202320222021
Net income-$-276.48M-$-337.71M-$-341.97M-$-290.51M-$-363.87M
Depreciation and amortization-$-1.39M$5.46M$5.27M$4.13M$3.92M
Stock-based compensation$62.4M$94.1M$86M$56.1M$48.5M
Change in working capital-$-23.31M$14.6M-$-32.46M$11.3M$97.3M
Accounts receivable$0.00$0.00$5.22M$100K$77.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-11.44M$0.00-$-2.39M$1.99M$930K
Net cash provided by operating activities-$-235.46M-$-249.11M-$-300.32M-$-229.49M-$-74.41M
Investments in property, plant and equipment-$-410K-$-2.02M-$-4.13M-$-9.06M-$-3.47M
Acquisitions, net$0.00$0.00$0.00$179.7M-$-25.3M
Net cash used for investing activities$192.8M-$-41.08M$257.6M-$-188.75M-$-479.51M
Common stock issued$1.6M$265.9M$30.3M$284.7M$382.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.6M$270.2M$34.8M$289.9M$388.1M
Net change in cash-$-41.05M-$-20.04M-$-7.93M-$-128.32M-$-165.83M
Cash at end of period$85.4M$126.4M$146.4M$154.4M$282.7M
Operating cash flow-$-235.46M-$-249.11M-$-300.32M-$-229.49M-$-74.41M
Capital expenditure-$-410K-$-2.02M-$-4.13M-$-9.06M-$-3.47M
Free cash flow-$-235.87M-$-251.12M-$-304.44M-$-238.55M-$-77.88M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Relay Therapeutics, Inc.

        Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

        CEO
        Sanjiv K. Patel
        Employees
        259
        Beta
        1.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Relay Therapeutics, Inc. (RLAY)?

        Relay Therapeutics, Inc. (RLAY) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RLAY undervalued?

        RLAY trades at a price of $16.12 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.